Two Sigma Advisers’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-393,100
Closed -$3.52M 1445
2025
Q4
$3.52M Sell
393,100
-478,400
-55% -$2.96M 0.01% 966
2025
Q3
$3.22M Buy
871,500
+416,600
+92% +$1.14M 0.01% 914
2025
Q2
$887K Buy
454,900
+96,100
+27% +$200K ﹤0.01% 1504
2025
Q1
$631K Sell
358,800
-117,600
-25% -$268K ﹤0.01% 1679
2024
Q4
$1.27M Sell
476,400
-57,500
-11% -$148K ﹤0.01% 1352
2024
Q3
$1.22M Sell
533,900
-211,900
-28% -$646K ﹤0.01% 1318
2024
Q2
$2.18M Sell
745,800
-272,800
-27% -$832K ﹤0.01% 1146
2024
Q1
$3.71M Sell
1,018,600
-128,300
-11% -$246K 0.01% 914
2023
Q4
$1.73M Buy
1,146,900
+412,200
+56% +$530K ﹤0.01% 1371
2023
Q3
$984K Buy
734,700
+79,500
+12% +$132K ﹤0.01% 1528
2023
Q2
$1.18M Buy
655,200
+27,000
+4% +$45.9K ﹤0.01% 1473
2023
Q1
$1.04M Sell
628,200
-73,500
-10% -$149K ﹤0.01% 1609
2022
Q4
$1.35M Buy
701,700
+319,500
+84% +$646K ﹤0.01% 1427
2022
Q3
$856K Buy
382,200
+263,500
+222% +$752K ﹤0.01% 1595
2022
Q2
$385K Buy
118,700
+97,000
+447% +$423K ﹤0.01% 2035
2022
Q1
$114K Buy
+21,700
New +$122K ﹤0.01% 2484

Other funds holding NUVB

Two Sigma Advisers's NUVB Position: Q1 2026 in Review

Two Sigma Advisers sold out of Nuvation Bio (NUVB) in Q1 2026, closing a stake of 393,100 shares — an estimated $3.52M sold.

Two Sigma Advisers first reported a position in NUVB in Q1 2022 and held it in 16 quarters. The position peaked at $3.71M in Q1 2024. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Two Sigma Advisers reported no remaining Nuvation Bio position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 393,100 Nuvation Bio shares in Q1 2026, an estimated $3.52M.
  • Two Sigma Advisers first reported a position in Nuvation Bio in Q1 2022 and held it in 16 quarters.
  • Two Sigma Advisers's Nuvation Bio position peaked at $3.71M in Q1 2024.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.